Dr. Wang has made distinguished contributions to the field of genetics of cardiovascular and neurological diseases by identifying eight genes for single gene disorders and three candidate genes for common complex disease, and by identifying novel molecular mechanisms underlying channelopathies and other diseases. He was noted for reporting the discoveries of the first Brugada syndrome gene (SCN5A), the most common gene for long QT syndrome (LQTS) (KCNQ1), one of the first two genes reported for LQTS in the same issue of Cell (SCN5A), LQTS gene KCNE1, the first gene for autosomal recessive atrial fibrillation (NUP155), atrial fibrillation gene SCN3B, the first gene for vascular disease Klippel-Trenaunay syndrome (AGGF1), and the first gene for co-existent paroxysmal dyskinesia and generalized epilepsy (KCNMA1). Dr. Wang also identified candidate genes for familial, early-onset coronary artery disease (CAD), completed the first genome-wide association study for CAD in a non-Caucasian population and identified C6orf105 as a new CAD susceptibility gene. Dr. Wang’s early discoveries on cardiac arrhythmias genes have been translated into the first commercial genetic testing kit in the field of cardiovascular medicine (Familion Test), which realized the first successful case of personalized genomic medicine in cardiovascular medicine and saved many human lives. Dr. Wang has identified a protein MOG1 that interacts with the cardiac sodium channel and regulates trafficking of this channel to cell membranes, and established AGGF1 as a VEGF-A-like angiogenic factor for specifying veins (in contrast to arterial specification by VEGF-A).
Qing Wang is currently Staff at Department of Molecular Cardiology, Department of Cardiovascular Medicine, and Neurological Institute, and the Director of Center for Cardiovascular Genetics at the Cleveland Clinic. He is Professor of Molecular Medicine and Professor of Genetics at Case Western Reserve University. He received B.S. from China in 1984, Ph.D. in Genetics and Developmental Biology from Cornell University in 1993, and M.B.A. from Cleveland State University in 2002. His postdoctoral research training was with Dr. Mark Keating at the Howard Hughes Medical Institute, University of Utah Health Sciences Center. Dr. Wang joined the faculty at Baylor College of Medicine as an Assistant Professor (tenure track) in 1996 and Cleveland Clinic as Assistant Staff in 1999. Dr. Wang has published more than 190 scientific papers and book chapters, and edited two volumes of Methods in Molecular Medicine. He is an elected Fellow of the American Association for the Advancement of Science. His research mostly focuses on finding genes for cardiovascular diseases, in particular, cardiac arrhythmias, syncope, seizures, and sudden death. He also uses a variety of technologies to identify novel molecular mechanisms and develop therapies for diseases.